Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoes Implantation with NVD-003, an Autologous Tissue Regeneration Product, in Phase 1b/2a US/EU Clinical Trial

Second patient scheduled for implantation with NVD-003 in June 2023 Pivotal trial is expected to begin in the second half of 2024* Novadip Biosciences SA ("Novadip" or "the Company"), a clinical-stage

Related Keywords

Brussels ,Bruxelles Capitale ,Belgium ,J Pediatr Orthop ,Pierre Louis Docquier ,Denis Dufrane ,Novadip Biosciences ,Acta Orthop Scand ,Gewinn Nur ,Novadip Bioscience ,Jim Heins ,Judy Ashworth ,University Hospital Saint Luc ,Development Programs ,Saint Luc University Hospital ,Congenital Pseudarthrosis ,Professor Pierre Louis Docquier ,Novadip Bioscience Chief Medical ,Clinical Proof ,Future Development ,Bone Joint ,Acta Orthop ,Dana Murdock ,Novadip ,Iosciences ,Nnounces ,First ,Pediatric ,Patient ,Congenital ,Seudoarthrosis ,Libia ,Undergoes ,Implantation ,Tautologous ,Issue ,Regeneration ,Product ,Hase ,Linical ,Trial ,